Innovative Solutions for Acute Myeloid Leukemia: The Role of EGFL7EGFL7-centric technology for diagnosis, prognosis, and therapeutic strategies for hematologic malignancies. The complex genetic landscape of Acute Myeloid Leukemia (AML), marked by chromosomal alterations and gene mutations, necessitates innovative approaches. The Need AML poses a significant challenge in the realm of hematologic malignancies, demanding both prognostic markers and novel treatments. Current gaps in understanding the complex genetic landscape, in particular the functional implications of the Epithelial Growth Factor-Like 7 (EGFL7) gene in AML, coupled with the need for prognostic markers, call for transformative solutions to enhance therapeutic outcomes. The Technology Researchers at The Ohio State University have developed a groundbreaking technology focusing on the pivotal role of EGFL7 in hematologic malignancies, marking a paradigm shift in AML treatment. Specifically, anti-EGFL7 antibodies emerge as a promising tool for preventing or treating hematologic malignancies. Additionally, EGFL7 expression levels serve as a prognostic marker, predicting a subject’s responsiveness to therapeutic agents, Leveraging EGFL7’s significance in hematopoiesis, recombinant EGFL7 presents a novel approach for expanding hematopoietic stem and progenitor cells (HSPCs).
Commercial Applications
Benefits/Advantages
Issued US Patent |
Tech IDT2017-126 CollegeLicensing ManagerSchultz, Teri InventorsCategories(None) |